☆ 4.7 Article

Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy

EUROPEAN JOURNAL OF CANCER (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future

Panagiotis Zoumpourlis et al.

Summary: Non-clear cell renal cell carcinoma (nccRCC) encompasses a diverse group of tumors, each requiring tailored treatment recommendations based on their histological characteristics. Systemic therapy options for metastatic nccRCC include targeted therapies, immune checkpoint inhibitors, and chemotherapy, with each histological subtype showing different responses to these regimens. Clinical and biological data play a crucial role in guiding systemic therapy recommendations for specific nccRCC subtypes.

CLINICAL GENITOURINARY CANCER (2021)

添加到收藏夹

Article Urology & Nephrology

Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021

Christina Canil et al.

CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2021)

添加到收藏夹

Article Oncology

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

David F. McDermott et al.

Summary: Single-agent pembrolizumab demonstrated promising antitumor activity as a first-line treatment in untreated patients with advanced ccRCC, with durable responses observed across different categories. The safety and tolerability profile of pembrolizumab monotherapy was consistent with what has been observed in other tumor types.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

Sumanta K. Pal et al.

Summary: In this study comparing different drug treatments for papillary renal cell carcinoma, cabozantinib was found to result in significantly longer progression-free survival compared to sunitinib, while savolitinib and crizotinib did not show an improvement in progression-free survival.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert Motzer et al.

Summary: The study demonstrated that the combination of lenvatinib with pembrolizumab led to significantly longer progression-free survival and overall survival than sunitinib, while the combination of lenvatinib with everolimus showed longer progression-free survival but not overall survival compared to sunitinib. Adverse events were more frequent in patients receiving lenvatinib-based treatments.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Editorial Material Urology & Nephrology

Systemic Therapy for Advanced Non-clear-Cell Renal Cell Carcinoma: Slow but Definite Progress

Daniel M. Geynisman et al.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities

Kevin Zarrabi et al.

Summary: Kidney cancer has various forms, with clear cell renal cell carcinoma being the most common type and all others categorized as non-clear cell renal cell carcinoma. Patients with non-clear cell renal cell carcinomas tend to have poorer outcomes and fewer treatment options. Recent advancements in understanding non-clear cell tumors have led to the development of more effective therapies, including immunotherapy, to improve the lives of these patients.

CANCERS (2021)

添加到收藏夹

Article Oncology

Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis

Jad Chahoud et al.

ONCOLOGIST (2020)

添加到收藏夹

Article Oncology

Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features

Bradley A. McGregor et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non- Clear Cell Renal Cell Carcinoma

Ruby Gupta et al.

CLINICAL GENITOURINARY CANCER (2020)

添加到收藏夹

Article Pathology

Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome

Juan Maria Roldan-Romero et al.

MODERN PATHOLOGY (2020)

添加到收藏夹

Article Oncology

Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study

Manon de Vries-Brilland et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma

Rana R. McKay et al.

CANCER IMMUNOLOGY RESEARCH (2018)

添加到收藏夹

Article Urology & Nephrology

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

Nizar M. Tannir et al.

EUROPEAN UROLOGY (2016)

添加到收藏夹

Article Oncology

Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

Andrew J. Armstrong et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Brian I. Rini et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)

添加到收藏夹

Article Oncology

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Daniel Y. C. Heng et al.

LANCET ONCOLOGY (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.